Categories: News

10x Genomics to Participate in Upcoming June Investor Conferences

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PLEASANTON, Calif., May 24, 2021 (GLOBE NEWSWIRE) — 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating virtually in the following investor conferences:

  • William Blair 41st Annual Growth Stock Conference
    Fireside Chat on Wednesday, June 2nd at 2:20 p.m. Eastern Time/11:20 p.m. Pacific Time
  • Goldman Sachs 42nd Annual Global Healthcare Conference
    Fireside Chat on Wednesday, June 9th at 3:50 p.m. Eastern Time/12:50 p.m. Pacific Time

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.10xgenomics.com/.

About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2019 based on publications and all of the top 20 global pharmaceutical companies by 2019 research and development spend, and have been cited in over 2,500 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises 1,100 issued patents and patent applications.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts
Media:
media@10xgenomics.com

Investors:
investors@10xgenomics.com

Staff

Recent Posts

Hemostemix Closes $469,366 Private Placement

Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

2 hours ago

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr.…

2 hours ago

Virbac : Declaration of the number of shares and voting rights 06/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of…

2 hours ago

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC…

2 hours ago

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner

The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of…

2 hours ago